Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28220320 | 0.78 | RET (0.36) | RETALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL2939407 | 0.76 | ACHE (0.33) | ALDH1A1 | |
| SCHEMBL2937446 | 0.76 | POLB (0.47) | RETALDH1A1SMN1; SMN2TDP1LMNA | |
| SCHEMBL15800724 | 0.76 | RET (0.53) | RETALDH1A1SMN1; SMN2LMNACYP2D6 | |
| SCHEMBL1131353 | 0.73 | — | — | |
| SCHEMBL8149969 | 0.73 | LMNA (0.35) | ALDH1A1SMN1; SMN2TDP1LMNACYP2D6 | |
| SCHEMBL19766703 | 0.71 | CA1 (0.38) | RETALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL21192353 | 0.71 | CA1 (0.38) | RETALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL251288 | 0.71 | DRD2 (0.41) | ALDH1A1SMN1; SMN2TDP1LMNA | |
| SCHEMBL5090888 | 0.71 | LMNA (0.33) | ALDH1A1SMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756027-B1 | PROCESS FOR PRODUCING INDENOL ESTERS OR ETHERS | FIRMENICH & CIE (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-7250528-B2 | Process for producing indenol esters or ethers | FIRMENICH SA (CH) | 2007-07-31 | — | — | US | disclosed |
| US-20070032402-A1 | Process for producing indenol esters or ethers | FIRMENICH SA (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20050261513-A1 | Process for producing indenol esters or ethers | FIRMENICH SA (CH) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032402-A1 | Process for producing indenol esters or ethers | NISCH, SULT2A1, SI | RET 2779/4885ALDH1A1 120/4885SMN1; SMN2 4330/4885 |
| US-20050261513-A1 | Process for producing indenol esters or ethers | NISCH, SI, SULT2A1 | RET 2777/4885ALDH1A1 95/4885SMN1; SMN2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.